Deciphera Pharmaceuticals (FRA:D05) 3-Year Book Growth Rate : -22.70% (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Deciphera Pharmaceuticals 3-Year Book Growth Rate?

Deciphera Pharmaceuticals's Book Value per Share for the quarter that ended in Dec. 2023 was €4.00.

During the past 12 months, Deciphera Pharmaceuticals's average Book Value per Share Growth Rate was -13.70% per year. During the past 3 years, the average Book Value per Share Growth Rate was -22.70% per year. During the past 5 years, the average Book Value per Share Growth Rate was -14.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 9 years, the highest 3-Year average Book Value per Share Growth Rate of Deciphera Pharmaceuticals was 18.70% per year. The lowest was -22.70% per year. And the median was -16.55% per year.

Competitive Comparison of Deciphera Pharmaceuticals's 3-Year Book Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Deciphera Pharmaceuticals's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Deciphera Pharmaceuticals's 3-Year Book Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Deciphera Pharmaceuticals's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Deciphera Pharmaceuticals's 3-Year Book Growth Rate falls into.

Deciphera Pharmaceuticals 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Deciphera Pharmaceuticals (FRA:D05) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Deciphera Pharmaceuticals 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Deciphera Pharmaceuticals's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Deciphera Pharmaceuticals (FRA:D05) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Deciphera Pharmaceuticals Inc (FRA:D05) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

DCPH:USA

Address

200 Smith Street, Waltham, MA, USA, 02451

Website

https://www.deciphera.com

Deciphera Pharmaceuticals Inc is a biotechnology company, which develops and manufactures kinase-inhibiting drugs for the treatment of cancers and immunological diseases. It holds a diverse pipeline of drug candidates that includes three clinical-stage and two research-stage programs. Its lead drug candidate DCC-2618 is designed to inhibit the full spectrum of mutant or amplified KIT and Pdgfra kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. In addition, it is also developing two other clinical-stage drug candidates, DCC-3014 and Rebastinib. Geographically all the operations function through the region of the United States.

Deciphera Pharmaceuticals (FRA:D05) Headlines

No Headlines